<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100084</url>
  </required_header>
  <id_info>
    <org_study_id>36864</org_study_id>
    <secondary_id>36259</secondary_id>
    <nct_id>NCT03100084</nct_id>
  </id_info>
  <brief_title>PREdelivery Placental Biomarkers- Pregnancy and Delivery Outcome</brief_title>
  <acronym>PREPPeD</acronym>
  <official_title>The PREPPeD Study: &quot;PREdelivery Placental Biomarkers- Pregnancy and Delivery Outcome&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian SIDS and Stillbirth Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Extrastiftelsen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PREPPeD study proposes that predelivery placenta-derived maternal circulating biomarkers
      reflect placental health, capacity and ageing, and can help predict onset and complications
      of delivery both in complicated pregnancies as well as in clinically uncomplicated
      term/post-term pregnancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main aim of the PREPPeD study is to explore whether placental health, evaluated by
      maternal blood biomarkers in late pregnancy, correlates with delivery outcomes in both
      healthy and complicated pregnancies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2016</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fetal acidaemia</measure>
    <time_frame>Umbilical cord gas/lactate are sampled directly post partum within 45 min; data assessed throughout study period of 140 months</time_frame>
    <description>In neonates delivered by cesarean section (CS) without labour (defined as absence of regular uterine contractions):
Umbilical artery blood (transporting blood from the fetus to the placenta) pH&lt;7.13 and arterial BD &gt;10.0
In neonates from labored delivery (regardless of subsequent delivery method, vaginal or CS):
Umbilical artery blood pH&lt;7.05 and arterial BD&gt;14; OR Umbilical artery blood lactate&gt;3.9 mmol/L (or umbilical vein lactate &gt;3.4 mmol/L if umbilical artery blood sample not available</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Newborn low Apgar score</measure>
    <time_frame>Apgar score is assessed directly post partum within 10 minutes; data assessed throughout study period of 140 months</time_frame>
    <description>&lt;4 at 1 minute OR &lt;7 at 5 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Newborn asphyxia</measure>
    <time_frame>Directly post partum within 10 and 45 minutes respectively; data assessed throughout study period of 140 months</time_frame>
    <description>Combination of outcomes 1 and 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of intrauterine fetal demise/intra-/postpartum fetal death</measure>
    <time_frame>Diagnosis within 28 days postpartum; data assessed throughout study period of 140 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neonatal intubation/mechanical ventilation&gt;6 hours</measure>
    <time_frame>Within 28 days postpartum; data assessed throughout study period of 140 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Meconium aspiration syndrome</measure>
    <time_frame>Diagnosis within 28 days postpartum; data assessed throughout study period of 140 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neonatal hypoxic-ischemic encephalopathy</measure>
    <time_frame>Diagnosis within 28 days postpartum; data assessed throughout study period of 140 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapeutic hypothermia of the neonate</measure>
    <time_frame>Within 3 days postpartum; data assessed throughout study period of 140 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of acute cesarean section (due to suspected fetal distress)</measure>
    <time_frame>Data assessed throughout study period of 140 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of operative vaginal deliveries (forceps/vacuum/combined; due to suspected fetal distress)</measure>
    <time_frame>Data assessed throughout study period of 140 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological placenta histology findings</measure>
    <time_frame>Data assessed throughout study period of 140 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal intrapartum CTG patterns</measure>
    <time_frame>Intrapartum CTG; data assessed throughout study period of 140 months</time_frame>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Pregnancy Complications</condition>
  <condition>Placental Insufficiency</condition>
  <arm_group>
    <arm_group_label>I. Post Dates</arm_group_label>
    <description>Pregnant women referred for clinical post term evaluation and/or labour induction.
Blood sampling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II. Induction of Labour</arm_group_label>
    <description>Pregnant women ≥37+0 GW (gestational week) referred for labour induction (any cause).
Blood sampling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III. All Outpatients</arm_group_label>
    <description>Pregnant women ≥37+0 GW presenting for any medical reason at OUH outpatient clinic.
Blood sampling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV. Diabetes in Pregnancy</arm_group_label>
    <description>Pregnant women ≥36+0 GW with pregestational or gestational diabetes. Blood sampling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V. Reduced Fetal Movements</arm_group_label>
    <description>Pregnant women ≥37+0 GW with reduced fetal movements and/or referred due to reduced symphysis-fundal height.
Blood sampling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VI. Hypertensive Disorders in Pregnancy</arm_group_label>
    <description>Pregnant women referred for preeclampsia (or other pregnancy induced hypertensive disorders) and/or suspected fetal growth restriction; longitudinal cohorts.
Blood sampling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VII. All Labour Admissions</arm_group_label>
    <description>All pregnant women ≥37+0 GW admitted for labour. Blood sampling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Maternal blood sampling</description>
    <arm_group_label>I. Post Dates</arm_group_label>
    <arm_group_label>II. Induction of Labour</arm_group_label>
    <arm_group_label>III. All Outpatients</arm_group_label>
    <arm_group_label>IV. Diabetes in Pregnancy</arm_group_label>
    <arm_group_label>V. Reduced Fetal Movements</arm_group_label>
    <arm_group_label>VI. Hypertensive Disorders in Pregnancy</arm_group_label>
    <arm_group_label>VII. All Labour Admissions</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Maternal plasma, serum and DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All pregnant women scheduled to deliver at the Department of Obstetrics at OUH who qualify
        for the study groups as specified in the &quot;Groups and Intervention&quot; section.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All pregnant women scheduled to deliver at the Department of Obstetrics at OUH who
             qualify for the study groups as specified in the &quot;Groups and Intervention&quot; section.

        Exclusion Criteria:

          -  Women who do not understand Norwegian or English

          -  Communicable disease

          -  Younger than 18 years of age

          -  Legally incompetent

          -  Fetal malformations
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meryam Sugulle, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital, Department of Obstetrics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meryam Sugulle, PhD, MD</last_name>
    <phone>+4722119800</phone>
    <email>uxsume@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Cathrine Staff, PhD, MD</last_name>
    <phone>+4722119800</phone>
    <email>uxnnaf@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meryam Sugulle, PhD, MD</last_name>
      <phone>+4722119800</phone>
      <email>uxsume@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Anne Cathrine Staff, PhD, MD</last_name>
      <phone>+4722119800</phone>
      <email>uxnnaf@ous-hf.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Meryam Sugulle</investigator_full_name>
    <investigator_title>Consultant Obstetrician</investigator_title>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>Diabetes in Pregnancy</keyword>
  <keyword>Fetal Growth Restriction</keyword>
  <keyword>Reduced Fetal Movements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Placental Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Depending on when the permission for the dataset usage for the project's outcome measures ends (OUH personal data officer/Regional Ethical Comittee) AND Norwegian legislation regarding personal data protection. It is unlikely that a major part of the data set will be shared openly due to these restrictions on sensitive personal data matters.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

